Ordering Recommendation

Recommended for the evaluation of membranous nephropathy in at-risk patients who test negative for PLA2R antibodies.

Mnemonic
THSD7A
Methodology

Semi-Quantitative Indirect Fluorescent Antibody

Performed

Tue

Reported

1-8 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum Separator Tube

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated

Remarks
Stability

Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval

Less than 1:10

Interpretive Data

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

If THSD7A Antibody, IgG is positive, then a THSD7A Antibody, IgG titer will be added. Additional charges apply.

Hotline History
N/A
CPT Codes

86255; if reflexed, add 86256

Components
Component Test Code* Component Chart Name LOINC
3003478 THSD7A Ab, IgG, Screen
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Antithrombospondin Type-1 Domain-Containing 7A (THSD7A) Antibody, IgG with Reflex to Titer